Literature DB >> 9027948

Fulminant hepatic failure: pediatric aspects.

B R Bhaduri1, G Mieli-Vergani.   

Abstract

In children, fulminant hepatic failure is a rare multisystem disorder in which severe impairment of liver function, with or without encephalopathy, occurs in association with hepatocellular necrosis in a patient with no recognized underlying chronic liver disease. Recognized etiologies include infections, toxins, metabolic disorders, infiltrative diseases, autoimmune hepatitis, ischemic or irradiation damage; a proportion of cases are cryptogenic. The diagnosis of the cause is essential to institute lifesaving medical treatment, decide if transplantation is indicated, and offer genetic counseling. The maximum International Normalized Ratio *(INR) reached during the course of the illness is the most sensitive predictor of outcome, mortality being 86% with an INR > or = 4, and 27% with an INR < 4 in our own series. Prognosis is worse in children younger than 2 years. Thus, urgent transplantation should be considered when the INR reaches 4, particularly in very young children. Survival after transplantation is 60% to 68%. Children with fulminant hepatic failure must be treated in specialized centers with facilities for liver transplantation.

Entities:  

Mesh:

Year:  1996        PMID: 9027948     DOI: 10.1055/s-2007-1007248

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  13 in total

1.  Inherited metabolic disorders presenting as acute liver failure in newborns and young children: King's College Hospital experience.

Authors:  Robert Hegarty; Nedim Hadzic; Paul Gissen; Anil Dhawan
Journal:  Eur J Pediatr       Date:  2015-04-24       Impact factor: 3.183

Review 2.  Ascites and encephalopathy in chronic liver disease.

Authors:  Winita Hardikar
Journal:  Indian J Pediatr       Date:  2002-02       Impact factor: 1.967

Review 3.  Acute liver failure.

Authors:  Marion M Aw; Anil Dhawan
Journal:  Indian J Pediatr       Date:  2002-01       Impact factor: 1.967

4.  Recurrent acute liver failure and mitochondriopathy in a case of Wolcott-Rallison syndrome.

Authors:  G Engelmann; J Meyburg; N Shahbek; M Al-Ali; M H Hairetis; A J Baker; R J T Rodenburg; D Wenning; C Flechtenmacher; S Ellard; J A Smeitink; G F Hoffmann; C R Buchanan
Journal:  J Inherit Metab Dis       Date:  2008-08-16       Impact factor: 4.982

Review 5.  Managing liver failure.

Authors:  D A Kelly
Journal:  Postgrad Med J       Date:  2002-11       Impact factor: 2.401

6.  Pediatric acute liver failure: variations in referral timing are associated with disease subtypes.

Authors:  Ekkehard Sturm; Willem S Lexmond; Henkjan J Verkade
Journal:  Eur J Pediatr       Date:  2014-07-09       Impact factor: 3.183

7.  Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure.

Authors:  Shihui Sun; Yan Guo; Guangyu Zhao; Xiaojun Zhou; Junfeng Li; Jingya Hu; Hong Yu; Yu Chen; Hongbin Song; Fei Qiao; Guilian Xu; Fei Yang; Yuzhang Wu; Stephen Tomlinson; Zhongping Duan; Yusen Zhou
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

8.  Hemadsorption with Adult CytoSorb® in a Low Weight Pediatric Case.

Authors:  Catalin Gabriel Cirstoveanu; Ileana Barascu; Samantha Mc Kenzie Stancu
Journal:  Case Rep Crit Care       Date:  2017-01-03

9.  Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program.

Authors:  Guillermo Cervio; Julio Trentadue; Daniel D'Agostino; Carlos Luque; Mariano Giorgi; Judith Armoni; Roberto Debbag
Journal:  Hepat Med       Date:  2011-09-19

10.  Acute liver failure in children-Is living donor liver transplantation justified?

Authors:  Marek Szymczak; Piotr Kaliciński; Grzegorz Kowalewski; Dorota Broniszczak; Małgorzata Markiewicz-Kijewska; Hor Ismail; Marek Stefanowicz; Adam Kowalski; Joanna Teisseyre; Irena Jankowska; Waldemar Patkowski
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.